Estrogen Receptor Alpha Expression in Ovarian Cancer Predicts Longer Overall Survival
Open Access
- 6 January 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Pathology and Oncology Research
- Vol. 17 (3), 511-518
- https://doi.org/10.1007/s12253-010-9340-0
Abstract
Estrogen as a potential factor of ovarian carcinogenesis, acts via two nuclear receptors, estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), but the cellular signal pathways involved are not completely clear so far. In this study we have described the expression of ERα, detected by immunocytochemistry in 11 ovarian carcinoma cell lines and by immunohistochemistry in 43 Federation Internationale des Gyneacologistes et Obstetristes stage III ovarian carcinoma specimens prepared before and after treatment with cisplatin-based schemes. For cisplatin resistance is a major obstacle in the treatment of ovarian carcinoma, analysis of cisplatin sensitivity in 11 ovarian carcinoma cell line was also performed. The strong nuclear ERα expression was only shown in the single A2780P cell line. Expression of ERα in tissue specimens did not reveal any correlations between histopathological parameters (histologic type and grading). We demonstrated a significant association with ERα expression in specimens from primary laparotomies (PL) and cause–specific survival. In the cases terminated by death of the patient, overall immunoreactivity score of ERα expression at PL was significantly lower than in surviving patients. In addition, Kaplan-Meier analysis revealed significantly shorter overall survival time and progression-free time in cases with lower immunoreactivity score of ERα expression at PL. Our findings support the hypothesis that aberrant hormone activity, by way of altered receptor expression, might be an important factor in the malignant transformation of ovarian cancer.Keywords
This publication has 31 references indexed in Scilit:
- Relationship between Epidemiologic Risk Factors and Hormone Receptor Expression in Ovarian Cancer: Results from the Nurses' Health StudyCancer Epidemiology, Biomarkers & Prevention, 2009
- RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cellsBiochemical and Biophysical Research Communications, 2006
- Protection of platinum–DNA adduct formation and reversal of cisplatin resistance by anti‐MRP2 hammerhead ribozymes in human cancer cellsInternational Journal of Cancer, 2005
- Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRPMolecular Therapy, 2005
- Estrogens and epithelial ovarian cancerGynecologic Oncology, 2004
- The biological role of estrogen receptors α and β in cancerCritical Reviews in Oncology/Hematology, 2004
- Expression of oestrogen receptor α and β in uterine endometrial and ovarian cancersEuropean Journal Of Cancer, 2002
- Recent advances in the treatment of epithelial ovarian cancerExpert Opinion on Investigational Drugs, 2001
- Absence of estrogen receptor-β expression in metastatic ovarian cancerPublished by Ovid Technologies (Wolters Kluwer Health) ,2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000